- Home
- BIIB vs AWK Comparison
BIIB vs AWK Comparison
Compare BIIB & AWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- AWK
- Stock Information
- Founded
- BIIB 1978
- AWK 1886
- Country
- BIIB United States
- AWK United States
- Employees
- BIIB N/A
- AWK N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- AWK Water Supply
- Sector
- BIIB Health Care
- AWK Utilities
- Exchange
- BIIB Nasdaq
- AWK Nasdaq
- Market Cap
- BIIB 25.1B
- AWK 28.5B
- IPO Year
- BIIB 1991
- AWK 2008
- Fundamental
- Price
- BIIB $160.92
- AWK $131.00
- Analyst Decision
- BIIB Buy
- AWK Hold
- Analyst Count
- BIIB 25
- AWK 8
- Target Price
- BIIB $258.57
- AWK $141.88
- AVG Volume (30 Days)
- BIIB 1.6M
- AWK 1.4M
- Earning Date
- BIIB 10-30-2024
- AWK 10-30-2024
- Dividend Yield
- BIIB N/A
- AWK 2.34%
- EPS Growth
- BIIB 10.05
- AWK 3.70
- EPS
- BIIB 11.06
- AWK 5.03
- Revenue
- BIIB $9,607,500,000.00
- AWK $4,515,000,000.00
- Revenue This Year
- BIIB N/A
- AWK $8.31
- Revenue Next Year
- BIIB N/A
- AWK $6.19
- P/E Ratio
- BIIB $14.55
- AWK $26.02
- Revenue Growth
- BIIB N/A
- AWK 9.24
- 52 Week Low
- BIIB $153.62
- AWK $113.34
- 52 Week High
- BIIB $268.30
- AWK $150.68
- Technical
- Relative Strength Index (RSI)
- BIIB 37.88
- AWK 35.65
- Support Level
- BIIB $158.44
- AWK $135.10
- Resistance Level
- BIIB $165.29
- AWK $139.49
- Average True Range (ATR)
- BIIB 4.00
- AWK 2.47
- MACD
- BIIB 1.10
- AWK -0.20
- Stochastic Oscillator
- BIIB 32.82
- AWK 6.24
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About AWK American Water Works Company Inc.
American Water Works is the largest investor-owned us water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's nonregulated business is water services for military bases, which operates under long-term contracts with regulated-like returns.